ADAP - アダプティミュ―ン・セラピュ―ティクス (Adaptimmune Therapeutics plc) アダプティミュ―ン・セラピュ―ティクス

 ADAPのチャート


 ADAPの企業情報

symbol ADAP
会社名 Adaptimmune Therapeutics PLC (アダプティミュ―ン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets find and genetically engineer TCR and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials which are directed to cancer testis antigens NY-ESO-1 MAGE-A4 and MAGE-A10.   アダプティミュ―ン・セラピュ―ティクスは、英国のバイオ医薬品企業。独自のT細胞レセプタ―・プラットフォ―ムによる新しい癌免疫治療製品の開発に焦点を当て事業を展開。主な製品候補には、癌抗原として親和性が強化されたT細胞レセプタ―治療薬のNY-ESO-1およびNY-ESOがある。   Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
本社所在地 60 Jubilee Avenue Milton Park Abingdon Oxfordshire OX14 4RY GBR
代表者氏名 James Julian Noble ジェームズジュリアンノーブル
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +44 1235-43-0000
設立年月日 41974
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 371人
url www.adaptimmune.com
nasdaq_url https://www.nasdaq.com/symbol/adap
adr_tso 66427089
EBITDA EBITDA(百万ドル) -84.89300
終値(lastsale) 13.2
時価総額(marketcap) 876837574.8
時価総額 時価総額(百万ドル) 1259.51
売上高 売上高(百万ドル) 48.68900
企業価値(EV) 企業価値(EV)(百万ドル) 1130.482
当期純利益 当期純利益(百万ドル) -92.72400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adaptimmune Therapeutics PLC - ADR revenues increased from $6.4M to $17.2M. Net loss increased 54% to $64.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 41% to $47.7M (expense) Other (expense) income net decrease from $3.7M (income) to $8.3M (expense).

 ADAPのテクニカル分析


 ADAPのニュース

   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD  2020/06/02 08:37:04 Smarter Analyst
Biopharma Adaptimmune Therapeutics (ADAP) has now announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at … The post Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD appeared first on Smarter Analyst .
   Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?  2020/06/02 04:38:00 Zacks Investment Research
Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.
   Adaptimmune's stock tumbles after plans for public stock offering  2020/06/01 10:09:11 MarketWatch
Shares of Adaptimmune Therapeutics PLC undefined tumbled 11% in premarket trading Monday, after the biopharmaceutical company focused on cancer treatments…
   Adaptimmune Shares Nearly Double On Promising Cancer T-Cell Therapy Data  2020/05/29 11:06:00 Benzinga
Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) shares were advancing strongly Friday following an updated clinical readout from the …
   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD  2020/06/02 08:37:04 Smarter Analyst
Biopharma Adaptimmune Therapeutics (ADAP) has now announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at … The post Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD appeared first on Smarter Analyst .
   Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?  2020/06/02 04:38:00 Zacks Investment Research
Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.
   Adaptimmune's stock tumbles after plans for public stock offering  2020/06/01 10:09:11 MarketWatch
Shares of Adaptimmune Therapeutics PLC undefined tumbled 11% in premarket trading Monday, after the biopharmaceutical company focused on cancer treatments…
   Adaptimmune Shares Nearly Double On Promising Cancer T-Cell Therapy Data  2020/05/29 11:06:00 Benzinga
Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) shares were advancing strongly Friday following an updated clinical readout from the …
   What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy Stock  2020/04/28 16:00:10 Zacks Investment Research
Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Adaptimmune Therapeutics : Chairman Letter for 2020 AGM | MarketScreener  2020/04/22 12:18:11 MarketScreener
Adaptimmune Therapeutics PLC Registered office: 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX, U.K. … | April 22, 2020
   Has Adaptimmune Therapeutics (ADAP) Outpaced Other Medical Stocks This Year?  2020/02/05 16:30:09 Zacks Investment Research
Is (ADAP) Outperforming Other Medical Stocks This Year?
   Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?  2020/02/03 14:13:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor Adaptimmune Therapeutics plc (ADAP).
   The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance  2020/01/15 13:22:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ): announced an oncology stem cell therapy pact with Astellas Pharma Inc. (OTC: ALPMY ). Applied Therapeutics Inc (NASDAQ: APLT ) Arvinas Inc (NASDAQ: ARVN ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Calithera Biosciences Inc (NASDAQ: CALA ) Editas Medicine Inc (NASDAQ: EDIT ) Eli Lilly And Co (NYSE: LLY ) Epizyme Inc (NASDAQ: EPZM ) Fate Therapeutics Inc (NASDAQ: FATE ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (provided 2020 guidance) Hologic, Inc. (NASDAQ: HOLX ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novo Nordisk A/S (NYSE: NVO ) NuVasive, Inc. (NASDAQ: NUVA ) Profound Medical Corp (NASDAQ: PROF ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) Revance Therapeutics Inc (NASDAQ: RVNC ) Syneos Health, Inc. (NASDAQ: SYNH ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Varian Medical Systems, Inc. (NYSE: VAR ) Viela Bio Inc (NASDAQ: VIE ) West Pharmaceutical Services Inc. (NYSE: WST ) XBiotech Inc (NASDAQ: XBIT ) (announced a tender offer to buy up to $420 million worth …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アダプティミュ―ン・セラピュ―ティクス ADAP Adaptimmune Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)